News
05 April 2018

Genoscience Pharma starts first-in-human dosing of GNS561 in patients with advanced liver cancer at the Jules Bordet Institute, Brussels

First-in-class small molecule with a new mechanism of action; two-year IND international clinical trial involving…
Read More
News
11 January 2018

Clinical significance of high expression of a specific solute carrier transporter in HCC.

Abstract #202913 Clinical significance of high expression of a specific solute carrier transporter in HCC.…
Read More
News
6 December 2017

Genoscience Pharma receives FDA approval for Phase Ib/IIa study of GNS561 in liver cancer

This new first-in-class molecule, with a new mechanism of action, will go through an IND…
Read More
News
2 April 2017

GNS561 a new quinoline derivative inhibits the growth of hepatocellular carcinoma in a cirrhotic rat & human PDX orthotopic mouse models

Firas Bassissi1, Zuzana Macek Jilkova2,3, Sonia Brun1, Jerome Courcambeck1, Jennifer Tracz1, Keerthi Kurma2,3, Gaël S…
Read More
News
16 March 2017

GNS561 is a new quinoline derivative with high efficacy on cancer stem cells from colorectal liver metastasis and hepatocellular carcinoma

Wild Question Marks and devious Semikoli, but the Little Blind Text didn’t...
Read More
News
11-15 November 2016

The Liver Meeting 2016

Marseilles, France, October 31, 2016 -Genoscience Pharma, a company focused on discovering and developing small…
Read More
News
24 February 2016

Four New Members in Our Board Directors

Marseilles, February 24, 2016 – Genoscience Pharma, a biopharmaceutical company dedicated to discovering and developing cancer…
Read More
News
6 February 2012

RFS Pharma and Genoscience Pharma enter Worldwide License Agreement with BioLineRx to develop and commercialize Hepatitis C Virus Protease Inhibitor

RFS Pharma and Genoscience Pharma enter Worldwide License Agreement with BioLineRx to develop and commercialize…
Read More
News
24 January 2012

BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today it has signed a…
Read More
News
19 June 2007

RFS Pharma and Genoscience Pharma Sign Joint Venture Agreement to Discover and Develop Protease Inhibitors

RFS Pharma, LLC, and Genoscience Pharma today announced the formation of a drug discovery joint…
Read More